The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for NeuroinflammationReportar como inadecuado

The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Immunology Research - Volume 2016 2016, Article ID 6430423, 9 pages -

Review Article

Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

State Key Laboratory of Medical Neurobiology, Department of Neurobiology and Institutes of Brain Science, School of Basic Medical Science, Fudan University, Shanghai 200032, China

Department of Maternal-Fetal Medicine, Pregnancy Research Centre and Department of Obstetrics and Gynaecology, Royal Women’s Hospital, University of Melbourne, Parkville, VIC 3052, Australia

School of Acupuncture, Massage and Rehabilitation, Yunnan University of Traditional Chinese Medicine, Kunming 650500, China

Shanghai Institute of Geriatrics, Huadong Hospital, Fudan University, Shanghai 200040, China

Received 16 February 2016; Accepted 26 April 2016

Academic Editor: Moisés E. Bauer

Copyright © 2016 Wenbin Wan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Neuropathic pain NPP is intolerable, persistent, and specific type of long-term pain. It is considered to be a direct consequence of pathological changes affecting the somatosensory system and can be debilitating for affected patients. Despite recent progress and growing interest in understanding the pathogenesis of the disease, NPP still presents a major diagnostic and therapeutic challenge. High mobility group box 1 HMGB1 mediates inflammatory and immune reactions in nervous system and emerging evidence reveals that HMGB1 plays an essential role in neuroinflammation through receptors such as Toll-like receptors TLR, receptor for advanced glycation end products RAGE, C-X-X motif chemokines receptor 4 CXCR4, and N-methyl-D-aspartate NMDA receptor. In this review, we present evidence from studies that address the role of HMGB1 in NPP. First, we review studies aimed at determining the role of HMGB1 in NPP and discuss the possible mechanisms underlying HMGB1-mediated NPP progression where receptors for HMGB1 are involved. Then we review studies that address HMGB1 as a potential therapeutic target for NPP.

Autor: Wenbin Wan, Lan Cao, Ramin Khanabdali, Bill Kalionis, Xiantao Tai, and Shijin Xia



Documentos relacionados